BreatheAmerica, a developer and manager of centers for patients suffering from allergies, sinusitis and asthma as well as diseases related to the immune system, has closed a $22m Series B equity investment.
The round was led by Essex Woodlands, with participation from existing investors.
The company intends to use the funds to develop new centers around the country.
Led by President and CEO Joseph Hutts, BreatheAmerica manages diagnostic and treatment centers for chronic airway and immune system related diseases with trained medical specialists, staffing, protocols, diagnostics, treatment services, and other resources.
The company currently operates centers in Albuquerque, NM and Tulsa, Oklahoma and ambulatory infusion centers in Nashville, Memphis, and Knoxville, TN. It plans to open 4-6 new centers per year.